Prostate-cancer screening.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.Molecular diagnosis & therapy · 2014
   Article
2. Implications of the new AUA guidelines on prostate cancer detection in the U.S.Current urology reports · 2014
   Article
3. Prostate-specific antigen screening can be beneficial to younger and at-risk men.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2013
   Article
4. Update of randomized trials for prostate cancer screening.Reviews in urology · 2013
   Article
5. Prostate-specific antigen screening: pro.Current opinion in urology · 2010
   Review

Corrections and comments

• Comment on
  Mortality results from a randomized prostate-cancer screening trial.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as